Rain Therapeutics Inc. (RAIN) Fundamentals

Rain Therapeutics Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
SHARE INFORMATION
Market Cap$ 99,221,744
Shares Outstanding26,529,878
Float6,508,898
Percent Float24.53%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 0
Latest Fiscal EPS$ -2.04
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions132
Institutional Holdings Date2022-05-31
Institutional Bought Previous 3 Months1,540,143
Institutional Holdings Percent70.6%
Institutional Sold Previous 3 Months3,766,985
Insider Holdings Date2022-05-31
Insider Bought Previous 3 Months14,468
Insider Holdings Percent14.2
Insider Sold Previous 3 Months14,468
Insider Shares Owned3,759,890
TRADING INFO
52 Week High$ 22.22
52 Week Low$ 2.15
52 Week High Change$ -78.59
21 Day Moving Average$ 2.6181
21 Day Extended Moving Average$ 2.7793
50 Day Moving Average$ 3.1292
50 Day Extended Moving Average$ 3.3867
200 Day Moving Average$ 9.2611
200 Day Extended Moving Average$ 8.0733
10 Day Average Volume714,231
20 Day Average Volume411,619
30 Day Average Volume290,749
50 Day Average Volume210,708
Alpha-0.121629
Beta2.1656
Standard Deviation0.184185
R20.272590
7 Day Price Change$ 1.42
7 Day Percent Change61.21%
21 Day Price Change$ 1.04
21 Day Percent Change38.52%
30 Day Price Change$ 1.46
30 Day Percent Change64.04%
Month to Date Price Change$ 1.42
Month to Date Percent Change61.21%
Quarter to Date Price Change$ -1.33
Quarter to Date Percent Change-26.23%
180 Day Price Change$ -10.39
180 Day Percent Change-73.53%
200 Day Price Change$ -8.81
200 Day Percent Change-70.19%
Year to Date Price Change$ -9.14
Year to Date Percent Change-70.96%

Rain Therapeutics Inc. (RAIN) Key Ratios

PROFITABILITY
EBIT Margin0.0%
EBITDA Margin0.0%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 0
Revenue Per Share$ 0.00
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book0.90
Total Debt To Equity0.00
Int Coverage-433.80
Current Ratio9.70
Leverage Ratio1.10
Quick Ratio9.50
Long Term Debt To Capital0.00
VALUATION MEASURES
PE Ratio-1.50
Enterprise Value$ -23,571,258
Price to Sales0.00
Price to Free Cash-1.90
PE High Last 5 Years0.00
Price To Book0.90
Price To Cash Flow0.00
PE Low Last 5 Years0.00
Price to Tangible Book0.90
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-67.28
Return on Equity-176.10
Return on Capital-174.50

Rain Therapeutics Inc. (RAIN) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorErnst & Young LLP
CEOAvanish Vellanki
Emplyoees44
Last AuditUQ
CIK0001724979
IndustryBiotechnology
SectorHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)(541714)
CONTACT INFO
Address8000 Jarvis Avenue
Suite 204
Newark, CA 94560
Websitehttps://www.rainthera.com
Facsimile-
Telephone+1 510 953-5559
Email-
Your Recent History
NASDAQ
RAIN
Rain Thera..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20220628 05:29:05